Skip to content
The Longevity Archive
Efocipegtrutide in all countries

Legal status · Australia

Is Efocipegtrutide legal in Australia?

InvestigationalMetabolicEvidence: Preliminary

No. Efocipegtrutide is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.

Efocipegtrutide in Australia at a glance

ClassificationInvestigational, not registered
TGA approval statusNot approved by TGA; investigational
Evidence levelPreliminary (research strength: Moderate)
ReviewedSep 2026

Classification and note come from the Efocipegtrutide profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.

What this means

  • 01

    Efocipegtrutide is being studied in registered clinical trials but has not received TGA marketing approval in Australia.

  • 02

    Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.

  • 03

    Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.

What Efocipegtrutide is

A triple GLP-1, GIP, and glucagon agonist developed mainly for metabolic liver disease.

Efocipegtrutide, also known as HM15211, is a long-acting triple agonist of the GLP-1, GIP, and glucagon receptors from Hanmi Pharmaceutical, developed with a particular focus on metabolic dysfunction-associated steatohepatitis (MASH). Like retatrutide it targets all three incretin-related pathways.

Mechanism: Agonizes GLP-1, GIP, and glucagon receptors, combining appetite, insulin, and energy-expenditure effects with liver-directed action.

Regulatory history: Investigational (Phase 2b in MASH completed mid-2026; results pending)

How TGA treats this kind of product

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Efocipegtrutide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.

Efocipegtrutide in other countries

Frequently asked questions

Is Efocipegtrutide legal in Australia?

No. Efocipegtrutide is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.

Can I buy Efocipegtrutide in Australia?

No approved product exists to buy. In Australia Efocipegtrutide is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.

Is Efocipegtrutide TGA approved?

No. In Australia Efocipegtrutide is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Investigational (Phase 2b in MASH completed mid-2026; results pending). Evidence level: Preliminary.

Related compounds in Australia

Full research profile

Mechanism, cited studies, FDA status and the full legal summary for Efocipegtrutide live on its compound profile.

Efocipegtrutide profile

This page is general information about the regulatory status of Efocipegtrutide in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.